Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed from the Food and Drug Administration’s (FDA) drug shortage list ...

A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

(Reuters) - A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Diabetes can be expensive to manage ... Your insurance formulary, or the official list of medications that your insurance covers, can help you determine how generics compare in cost to brand ...